期刊文献+

制附子在治疗多发性硬化中的作用探讨 被引量:1

下载PDF
导出
摘要 目的:观察对多发性硬化(MS)起主要作用的中草药。方法:患者首次就诊后即进行长期随访,采用中药治疗,复发前后均检测Th1、Th2,通过频数统计选出主要药物,通过SPSS17.0软件将主要药物与Th1、Th2的关系进行统计分析。结果:使用制附子前后Th1的下降具有显著统计学差异(P<0.05);制附子对Th2的影响以及赤芍对Th1、Th2的影响不具有统计学差异(P>0.05)。结论:制附子可使Th1下降,对MS复发具有缓解作用,具有进一步研究价值。
作者 周宇倩
出处 《长治医学院学报》 2014年第4期296-297,共2页 Journal of Changzhi Medical College
  • 相关文献

参考文献7

  • 1Ochi H, Feng-Jun M* Osoegawa M, et al. Time-dependentcytokine deviation toward the Th2 side in Japanese multiplesclerosis patients with interferon beta-1 b. J Neurol Sci, 2004? 222?1-2) :65-73.
  • 2周宇倩,毛文琴,张晓君,李涛.疏肝健脾固髓方对多发性硬化复发的影响初步报告[J].中国中西医结合杂志,2013,33(1):31-34. 被引量:17
  • 3McDonald W I, Compston A, Edan G,et al. Recommendeddiagnostic criteria for multiple sclerosis: guidelines frominternational panel on the diagnosis of multiple sclerosis[J]. AnnNeurol,2001,50(1) :121-127.
  • 4Beebe A Cua D J, de Waal Malefyt R. The role ofinterleukin-10 in autoimmune diease j systemic lupus erythematosus(SLE) and multiple sclerosis (MS), Cytokine Growth Factor Rev,2002,13(4-5),403-412.
  • 5Vranes Z,Poljakovic Z. Marusic M. Natural kill cell numberand activity in multiple sclerosis. J Neurol Sci, 1989,94(1-3):115-123.
  • 6Chan S H? Kobayashi M, Santoli D,et al. Mechanisms ofIFN - gamma induction by natural killer cell stimulatory factor(NKSF/IL-12). Role of transcription and mRNA stability in thesynergistic interaction between NKSF and IL-2. J Immunol, 1992,148(1):92-98.
  • 7单保恩,张金艳,李巧霞,乔芳,李宏,叶静,杜肖娜,山下优毅,黑田悦史.白附子对人T细胞和单核细胞的调节活性[J].中国中西医结合杂志,2001,21(10):768-772. 被引量:34

二级参考文献22

  • 1王殿华,李永利,平阳.益髓灵胶囊治疗多发性硬化60例临床观察[J].山东中医杂志,2005,24(3):151-152. 被引量:10
  • 2张晓雪.补肾益气活血汤治疗多发性硬化49例临床观察[J].山西中医,2006,22(2):13-14. 被引量:16
  • 3樊永平,王平,张星虎,龚海洋,周莉,刘秀贞,王蕾.二黄方治疗多发性硬化急性发作的临床观察[J].北京中医药大学学报,2006,29(4):273-276. 被引量:35
  • 4李金才.白芍食疗的回顾与展望[J].中药通报,1987,(8):54-54.
  • 5Myhr KM, Mellgren SI. Corticosteroids in the treatment of multiple sclerosis [ J ]. Acta Neurol Scand Suppl, 2009, (189) : 73 -80.
  • 6Comi G,Hartung HP, Martinelli BF. Evidence for use of glatiramier acetate in multiple sclerosis [J]. Lancet Neuron, 2005, 4(2) : 75 -76. Discus- sion 76 -77.
  • 7Paniteh H, Goodin DS, Franeis G, et al. Random- ized, comparative study of interferon beta la treatment regiments in MS: the Evidence Trial [J:. Neurology, 2002, 59(10): 1496-1506.
  • 8McDonald Wl, Compston A, Edan G, et al. Rec- ommended diagnostic criteria for multiple sclero- sis: guidelines from international panel on the di- agnosis of multiple sclerosis [ J]. Ann Neurol, 2001 , 50(1) : 121 -127.
  • 9Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an inter- national survey. National Multiple Sclerosis Socie- ty (USA)Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis [ J ]. Neurology, 1996,46(4) : 907 -911.
  • 10Yokoyama H, Hiai S, Oura H, et al. Effects of to- tal of saponins extracted from several crude drugs on rat adrenocortical hormone secretion [J]. Yakugaku Zasshi,1982, 102(6) : 555 -559.

共引文献49

同被引文献15

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部